Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PGSXC-D2A
- Development stage
- Preclinical
- Lead developer
- PrimeGen Biotech
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
PGSXC-D2A is an investigational cell therapy developed by PrimeGen for the treatment of Type 2 Diabetes Mellitus. It utilizes the company's proprietary stemXcell platform, which consists of Triple Activated Mesenchymal Stem Cells (MSCs). These cells are engineered to enhance their natural immunomodulatory and paracrine signaling properties, aiming to reduce systemic inflammation and support tissue repair in metabolic disease contexts. As of early 2026, the asset is listed in PrimeGen's pipeline as a pending program following the completion of pre-IND activities for other candidates in the same platform.
- Other names
- stemXcellTriple Activated Mesenchymal Stem Cells
Beyond the preview
Go deeper on PGSXC-D2A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PGSXC-D2A.